Literature DB >> 24875066

Pro re nata (as needed) psychotropic medication use in patients with borderline personality disorder and subjects with other personality disorders over 14 years of prospective follow-up.

Eduardo Martinho1, Garrett M Fitzmaurice, Frances R Frankenburg, Mary C Zanarini.   

Abstract

The use of pro re nata (PRN; as needed) psychotropic medication in patients with borderline personality disorder (BPD) has not been well characterized. This study had 3 purposes, which are as follows: (1) to describe the prevalence of PRN psychotropic medication use among patients with BPD and comparison subjects with other personality disorders (OPD) over 14 years of prospective follow-up, (2) to examine the rates reported by patients with BPD who ever recovered and never recovered, and (3) to examine the reasons for taking PRN medication reported by these patients. Overall, the prevalence of PRN psychotropic medication use was initially approximately 3 times higher among patients with BPD than comparison subjects with OPD, with a significant one-third decline in the use of PRN medication reported by patients with BPD over time. In analyses restricted to patients with BPD, patients with BPD who never recovered were approximately twice as likely to use PRN medication than patients with BPD who ever recovered over time. In reasons for use, the rates of PRN medication use to decrease agitation for both diagnostic groups declined significantly over time, whereas they remained significantly higher among patients with BPD. Likewise, patients with BPD who never recovered reported higher use of PRN medication to decrease agitation than patients with BPD who ever recovered over time. The results of this study indicate that PRN psychotropic medication is widely used for the treatment of patients with BPD, particularly those who have not achieved a recovery in both the symptomatic and psychosocial realms. They also suggest that patients with BPD use proportionally more PRN medication to decrease agitation than comparison subjects with OPD, with lower proportional use to reduce agitation found among recovered patients with BPD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24875066      PMCID: PMC4077949          DOI: 10.1097/JCP.0000000000000132

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  25 in total

1.  Treatment, management, and control: improving outcomes through more treatment and less control.

Authors:  R H Hunter
Journal:  New Dir Ment Health Serv       Date:  2000

2.  Inter-rater and test-retest reliability of the Revised Diagnostic Interview for Borderlines.

Authors:  Mary C Zanarini; Frances R Frankenburg; A Anna Vujanovic
Journal:  J Pers Disord       Date:  2002-06

3.  The diagnostic Interview for Personality Disorders: interrater and test-retest reliability.

Authors:  M C Zanarini; F R Frankenburg; D L Chauncey; J G Gunderson
Journal:  Compr Psychiatry       Date:  1987 Nov-Dec       Impact factor: 3.735

4.  Attainment and maintenance of reliability of axis I and II disorders over the course of a longitudinal study.

Authors:  M C Zanarini; F R Frankenburg
Journal:  Compr Psychiatry       Date:  2001 Sep-Oct       Impact factor: 3.735

5.  Alprazolam-induced dyscontrol in borderline personality disorder.

Authors:  D L Gardner; R W Cowdry
Journal:  Am J Psychiatry       Date:  1985-01       Impact factor: 18.112

6.  Mental health service utilization by borderline personality disorder patients and Axis II comparison subjects followed prospectively for 6 years.

Authors:  Mary C Zanarini; Frances R Frankenburg; John Hennen; Kenneth R Silk
Journal:  J Clin Psychiatry       Date:  2004-01       Impact factor: 4.384

7.  The longitudinal course of borderline psychopathology: 6-year prospective follow-up of the phenomenology of borderline personality disorder.

Authors:  Mary C Zanarini; Frances R Frankenburg; John Hennen; Kenneth R Silk
Journal:  Am J Psychiatry       Date:  2003-02       Impact factor: 18.112

8.  Absence of evidence that the pro re nata regimen confers benefit: a review of the studies.

Authors:  Kazunari Yoshida; Takefumi Suzuki; Hiroyuki Uchida; Masaru Mimura
Journal:  Int Clin Psychopharmacol       Date:  2013-09       Impact factor: 1.659

9.  Naturalistic manner of benzodiazepine use and cognitive behavioral therapy outcome in panic disorder with agoraphobia.

Authors:  Henny A Westra; Sheffy H Stewart; Brent E Conrad
Journal:  J Anxiety Disord       Date:  2002

10.  P.R.N. (As-needed) orders and exposure of psychiatric inpatients to unnecessary psychotropic medications.

Authors:  Purushottam B Thapa; Shanna L Palmer; Richard R Owen; Andrea L Huntley; James A Clardy; Laurence H Miller
Journal:  Psychiatr Serv       Date:  2003-09       Impact factor: 3.084

View more
  2 in total

1.  [Inhaled loxapine for emergency treatment of agitated patients with borderline personality disorder : A series of five cases].

Authors:  T H C Krüger; M A Wollmer; P Negt; H Frieling; S Jung; K G Kahl
Journal:  Nervenarzt       Date:  2016-11       Impact factor: 1.214

Review 2.  What Works in the Treatment of Borderline Personality Disorder.

Authors:  Lois W Choi-Kain; Ellen F Finch; Sara R Masland; James A Jenkins; Brandon T Unruh
Journal:  Curr Behav Neurosci Rep       Date:  2017-02-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.